Positive grass allergy tablet data from Merck as advisory meeting looms
This article was originally published in Scrip
Executive Summary
Merck has reported positive results for its Timothy grass sublingual immunotherapy tablet (MK-7243), licensed from ALK, including pediatric data. The BLA for the product was filed in January this year, and accepted for review in March (scripintelligence.com, 28 March 2013). Merck expects the US FDA's review for to be completed in the first half of 2014, but has not released the PDUFA date.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.